First-in-class small molecule inhibitor designed with AI support shows promise against pancreatic cancer in preclinical studies
August 05, 2026
August 05, 2026
ROCHESTER, Minnesota, Aug. 5 [Category: BizHospital] -- The Mayo Clinic issued the following news release:
* * *
First-in-class small molecule inhibitor designed with AI support shows promise against pancreatic cancer in preclinical studies
*
JACKSONVILLE, Fla. -Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the "undruggable" PDZ-domain of GIPC1 protein that helps di . . .
* * *
First-in-class small molecule inhibitor designed with AI support shows promise against pancreatic cancer in preclinical studies
*
JACKSONVILLE, Fla. -Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the "undruggable" PDZ-domain of GIPC1 protein that helps di . . .